drugset / Trial / NCT00640523
Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the effectiveness and safety of forodesine in CLL patients
Timeline
- Start
- 2008-03
- Primary completion
- 2010-11
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | forodesine | Small molecule | 200 mg | — |